Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials

Thoracic Cancer

Volumn 2, Issue 4, 2011, Pages 213-220

  Jiang, Jin ^a   Wang, Xiaojing ^a   Tian, Jinhui ^a   Li, Lun ^a   Lin, Qiao ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Chemotherapy; NSCLC; Thymosin

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; THYMOPENTIN; THYMOSIN; THYMOSIN ALPHA1;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NATURAL KILLER CELL; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84861393221     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2011.00057.x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2006. Cancer J Clin 2006; 56: 106-30.
2. American Cancer Society. Cancer Facts and Figures 2007. American Cancer Society, Atlanta, GA 2007.
3. Rossi A, Maione P, Gridelli C. Cetuximab in advanced non-small cell lung cancer. Crit Rev Oncol Hematol 2006; 59: 139-49.
4. Dunn GP, Bruce AT, Ikeda H etal. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2003; 3: 991-8.
5. Simon G, Ginsberg RJ, Ruckdeschel JC. Small-cell lung cancer. Chest Surg Clin N Am 2001; 11: 165-88.
6. Ruttinger D, Winter H, van den Engel NK etal. Immunotherapy of lung cancer: an update. Onkologie 2006; 29: 33-8.
7. Chen C, Li M, Yang H etal. Roles of thymosins in cancers and other organ systems. World J Surg 2005; 29: 264-70.
8. Low TL, Thurman GB, McAdoo M etal. The chemistry and biology of thymosin. l. Isolation characterization, and biological activities of thymosin alphal and polypeptide betal from calf thymus. J Biol Chem 1979; 254: 981-6.
9. Body B. Thymic hormones in cancer diagnostics and treatment [J]. Expert Opin Biol Ther 2001; 1: 93-107.
10. Schlesinger DH, Goldstein G, Scheid MP etal. Chemical synthesis of a peptide fragment of thymopoietin II that induces selective T cell differentiation. Cell 1975; 5: 367-70.
11. Department of Medical Administration of Ministry of Health of the People's Republic of China. Guideline of Normal Cancer Diagnosis and Treatment in China. 9th Branch. Main Measurement Indexes and Statistical Methods in Normal Cancer in China. Beijing Medical University and China Union Medical University Press, Beijing 1991; 11-15.
12. Park JO, Lee SI, Song SY etal. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003; 33: 533-7.
13. Miller AB, Hoogstraten B, Staquet M etal. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
14. Higgins JPT, Green S. Cochrane Handbook for Systematic Review of Intervention Version 5.01 (updated September 2008). The Cochrane Collaboration, 2008. [cited 19 June 2011]. Available from:.
15. Review Manager (RevMan) (Computer program). Version 5.0.Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration. 2008.
16. Tugwell P, Shea B, Boers M etal. Methodology in rheumatology. In: Tugwell P, Shea B, Boers M etal (eds). Evidence-Based Rheumatology. BMJ Books, London 2004; 19-25.
17. Gu AQ, Xiong LW, Xin Y etal. Effect of thymosin for patients with advanced non-small cell lung cancer (NSCLC) in chemotherapy. China Oncol 2007; 17: 493-5.
18. Hou XR. Clinical effects of advanced patients with non-small cell lung cancer treatment by thymosin alpha 1 combined with NP regimens. J Bethune Mil Med Coll 2007; 5: 272-4.
19. Liu PH, Liao GQ, Wang HM. Influence of thymopentin on immunologic function in advanced-stage patients with nonsmall-cell lung cancer. J Xinxiang Med Coll 2008; 25: 289-91.
20. Ma DT, Lin DJ, Li M etal. Thymosin-a1 in the treatment of patients with non-small cell lung cancer. Shandong Med J 2006; 46: 77.
21. Shi X, Ding Q, Yang L. The application of Thymosin-a1 plus chemotherapy in the treatment of advanced non-small cell lung cancer. PJCCPVD 2007; 15: 764-6.
22. Liang B, Zhou Z, Yang JM. Combination of thymosin-a1 with low-dose gemcitabine for advanced non-small cell lung cancer in elderly patients. J Pract Oncol 2010; 25: 470-3.
23. Lin F. Efficiency of thymopentin plus chemotherapy in the treatment of non-small cell lung cancer. Chongqing Med J 2009; 38: 2060-2.
24. Shen W. Efficacy of thymosin combined with chemotherapy in non-small cell lung cancer. Chin J Hemorh 2008; 18: 378-80.
25. Sun XM, Gao F, Liu XM etal. Cellular immune function of thymosin-a1 on patients with non-small cell lung cancer during chemotherapy. Shandong Med J 2009; 49: 83-4.
26. Wang WF, Dong XF, Xin JH etal. Clinical observation on healing 42 case advanced lung cancer with thymosin and GP program. China Med Her 2008; 5: 53-4.
27. Atkins D, Best D, Briss PA etal. Grading quality of evidence and strength of recommendation. BMJ 2004; 328: 1490.
28. Zhang YP, Jiang MN, Sun J. Advance of Research and Application of Immunomodulator. Prog Mod Biomed 2009; 9: 3191-3.
29. Ancell CD, Phipps J, Young L. Thymosin alpha-1[J]. Am J Health Syst Pharm 2001; 58: 879-85.